QELBREE 200 mg/1

QELBREE 200 mg is an extended-release capsule containing viloxazine hydrochloride, used for managing certain mental health conditions. This medication is designed to provide sustained relief and is manufactured by Supernus Pharmaceuticals, Inc.

QELBREE 200 mg is primarily used to address symptoms associated with attention deficit hyperactivity disorder (ADHD). Viloxazine hydrochloride, the active ingredient, works to help improve focus and reduce impulsivity. This medication is often prescribed as part of a comprehensive treatment plan that may include behavioral therapy and lifestyle modifications.

Common effects of QELBREE 200 mg may include improvements in concentration and a reduction in hyperactive behaviors. Some individuals may experience mild side effects such as nausea, headache, or insomnia. These effects can vary and are not experienced by everyone who takes the medication.

QELBREE 200 mg should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. This medication should not be shared with others, even if they have similar symptoms.

QELBREE 200 mg may interact with certain medications, including those that affect the central nervous system. It is advisable to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements, to avoid potential interactions. Alcohol consumption should be discussed with a healthcare professional.